The Federal Trade Commission released a second interim report showing that the three largest pharmacy benefit managers — CVS Caremark, Express Scripts and OptumRX — marked up specialty generic drug prices, generating over $7.3 billion in excessive revenues from 2017 to 2022.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
